GlaxoSmithKline’s (GSK) Buy Rating Reiterated at UBS Group
UBS Group reaffirmed their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research report released on Wednesday morning, Borsen Zeitung reports. They currently have a GBX 1,900 ($24.99) price target on the stock.
A number of other brokerages have also recently issued reports on GSK. Credit Suisse Group restated a neutral rating and set a GBX 1,860 ($24.47) price objective (up previously from GBX 1,860 ($24.47)) on shares of GlaxoSmithKline in a report on Thursday, February 6th. Barclays reduced their price objective on GlaxoSmithKline from GBX 1,650 ($21.70) to GBX 1,550 ($20.39) and set an underweight rating for the company in a report on Friday, February 7th. Shore Capital restated a hold rating on shares of GlaxoSmithKline in a report on Thursday, January 16th. Jefferies Financial Group restated a buy rating on shares of GlaxoSmithKline in a report on Monday, January 20th. Finally, HSBC set a GBX 2,110 ($27.76) price objective on GlaxoSmithKline and gave the stock a buy rating in a report on Wednesday, December 18th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of GBX 1,852.87 ($24.37).
Shares of LON:GSK opened at GBX 1,668.60 ($21.95) on Wednesday. GlaxoSmithKline has a 12-month low of GBX 1,485.20 ($19.54) and a 12-month high of GBX 1,857 ($24.43). The stock has a market cap of $83.70 billion and a PE ratio of 18.02. The business has a 50 day moving average of GBX 1,786.22 and a 200-day moving average of GBX 1,726.11. The company has a quick ratio of 0.51, a current ratio of 0.81 and a debt-to-equity ratio of 166.19.
In related news, insider Judy Lewent purchased 788 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was acquired at an average cost of GBX 2,344 ($30.83) per share, for a total transaction of £18,470.72 ($24,297.18). Over the last quarter, insiders purchased 810 shares of company stock valued at $1,885,602.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.